Successor found for CEO

Sana Alajmovic has been appointed as the new CEO of the Swedish company Enzymatica AB by the Board of Directors. The current CEO, Claus Egstrand, will become a member of the Board.

At the end of June, both CEO Claus Egstrand and CFO Therese Filmersson announced their resignation from the management of Lund-based Enzymatica AB. Now, at least Egstrand’s successor has been found. Sana Alajmovic will take over the position by the end of January 2026 at the latest. Egstrand will become a member of the Board of Directors.

Alajmovic is co-founder and current CEO of Sigrid Therapeutics. She brings extensive experience in business development and leadership in the life sciences sector and a successful track record in commercialising research results and building strategic partnerships with international pharmaceutical and healthcare companies.

The ‘Most Important Founder’ (award from the newspaper Dagens Industri in 2021) and ‘Leader of the Future’ (2020+2021 from the Swedish manager organisation Ledarna) will “focus on leading Enzymatica into its next phase of growth”.